Transcode Therapeutics Inc Stock Price, News & Analysis

TransCode Therapeutics (NASDAQ: RNAZ) has announced that it has regained compliance with Nasdaq's listing requirements, including minimum bid price and shareholders' equity rules. The company has also resolved a violation regarding the Shareholder Approval Rule through shareholder ratification of a July 2024 equity transaction.

The company will remain listed on the Nasdaq Capital Market but will be subject to a Discretionary Panel Monitor through December 24, 2025. If TransCode fails to maintain compliance with any listing rule during this period, it will not be granted additional time to regain compliance and may face delisting, though it will have the opportunity to request a new hearing.

Tom Fitzgerald, TransCode's Interim CEO and CFO, expressed optimism about the company's future, highlighting their focus on advancing their lead therapeutic candidate, TTX-MC138, in clinical trials.

TransCode Therapeutics (NASDAQ: RNAZ) announced the Safety Review Committee's unanimous approval to open the third cohort in its Phase 1 clinical trial of TTX-MC138, following favorable safety data from Cohort 2. The trial evaluates TTX-MC138, designed to inhibit microRNA-10b, which is important in metastatic cancer progression.

Key findings include: no significant safety or dose-limiting toxicities reported in Cohort 2; Cohort 3 will receive approximately double the dose of Cohort 2; pharmacokinetic and pharmacodynamic data from Cohort 1 align with preclinical and Phase 0 results, showing 66% inhibition of miR-10b at 24 hours post-infusion. The concentration of TTX-MC138 in human blood plasma exceeded levels achieved in nonclinical studies.

TransCode Therapeutics (RNAZ) has announced a 1-for-33 reverse stock split effective December 4, 2024, at 12:01 a.m. EST. The split aims to increase the per-share trading price to meet Nasdaq's minimum bid price requirement for continued listing. The split will reduce outstanding common shares from 17,265,658 to approximately 696,233 shares. The company's stock will continue trading under 'RNAZ' on the Nasdaq Capital Market. Proportional adjustments will be made to stock options, warrants, and shares under incentive plans. Stockholders will have fractional shares rounded up to the nearest whole number.

TransCode Therapeutics (Nasdaq: RNAZ) has announced an $8 million private placement with institutional investors. The company will issue 21,220,160 shares of common stock along with Series C and Series D warrants. The combined purchase price is $0.377 per share, with warrants exercisable at $0.475. Series C warrants have a 5-year term while Series D warrants have a 2.5-year term. The Benchmark Company is acting as exclusive placement agent, with closing expected around November 29, 2024. The proceeds will be used for general corporate purposes and working capital.

TransCode Therapeutics (RNAZ) announced a Board-approved 1-for-33 reverse stock split, which was approved by stockholders on November 22, 2024. The split aims to increase the per-share trading price to meet Nasdaq's minimum bid price requirements for continued listing. The split will reduce outstanding shares from 17,265,658 to approximately 523,202. Proportional adjustments will be made to stock options, warrants, and shares under incentive plans. No fractional shares will be issued, with fractions rounded up to the nearest whole number. The effective date is pending announcement.

TransCode Therapeutics (NASDAQ: RNAZ) has issued an open letter to shareholders regarding an upcoming Special Meeting on November 22. The company is seeking shareholder authorization for a potential reverse stock split to maintain Nasdaq listing compliance. The split would only be implemented if the stock fails to maintain a $1.00 per share closing price for any ten-day period before December 31, 2024.

Management emphasizes this measure is important for maintaining Nasdaq listing, which they consider critical for raising needed capital to continue clinical trials and operations. The company warns that delisting would likely have a material adverse effect on company and stock value.

TransCode Therapeutics (RNAZ) has received a notice from Nasdaq granting its request to maintain its listing on The Nasdaq Stock Market, subject to specific compliance conditions. The decision follows TransCode's appearance before the Nasdaq Hearings Panel on October 1, 2024. The Panel issued a Public Reprimand Letter regarding compliance issues with listing standards, including bid price requirements, equity requirements, and shareholder approval of certain transactions.

TransCode Therapeutics (NASDAQ: RNAZ) announced that the Safety Review Committee (SRC) has unanimously approved opening the second cohort in its Phase 1 clinical trial of TTX-MC138, following a favorable safety review of Cohort 1 data. TTX-MC138, designed to inhibit microRNA-10b important in metastatic cancer progression, showed no significant safety or dose-limiting toxicities in the first cohort. All patients from Cohort 1 remain on study, and the second cohort will receive approximately double the initial dose. TransCode is notably the only company with an ongoing US clinical trial targeting microRNA in cancer, utilizing technology recognized by the 2024 Nobel Prize in Physiology and Medicine.

TransCode Therapeutics (NASDAQ: RNAZ) has completed initial dosing of the first cohort in its Phase 1a dose-escalation clinical trial for TTX-MC138, an antisense oligonucleotide designed to inhibit microRNA-10b, a driver of metastasis in multiple cancers. Key points:

• All patients in the cohort received their first dose and remain on study for continued treatment
• No significant safety or dose limiting toxicities reported
• TTX-MC138 uses TransCode's proprietary TTX delivery system
• TransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer
• The trial's progress coincides with the 2024 Nobel Prize in Physiology and Medicine recognizing microRNA technology

The company views the rapid enrollment and absence of dose limiting toxicities as encouraging signs for the continued assessment of TTX-MC138's safety and tolerability.